GLP-1 microdosing means deliberately using a dose below the approved maintenance range, and no regulator has ever approved a microdose protocol for weight, metabolic health or longevity. There are no randomized trials of microdosing as a strategy. What does exist, and what almost no article on this subject mentions, is randomized dose-response data. In a 52 week phase 2 trial of daily semaglutide in adults with obesity, the lowest dose tested produced 6.0% weight loss against 2.3% for placebo, while the highest dose produced 13.8%. Low doses are not inert. They also are not equivalent, and the published figures let you see roughly what you give up.
This is an evidence review rather than a recommendation. Generational Health prescribes GLP-1 medication only after a medical evaluation, and the dose is a clinical decision made for an individual patient, not a protocol you select from a chart.
What counts as a microdose of a GLP-1?
There is no official definition, which is the first thing worth knowing. In practice the term is used for any regimen that deliberately stays below the approved maintenance dose, either by staying at an early titration step indefinitely or by splitting a dose further.
For context, here is what the approved ladders actually look like. Semaglutide for weight management starts at 0.25 mg once weekly and steps up over roughly four months to a standard maintenance dose of 2.4 mg. Tirzepatide starts at 2.5 mg once weekly for four weeks, a dose its own label states is for initiation only and is not approved as a maintenance dose, then moves to maintenance at 5, 10 or 15 mg. So a person describing themselves as microdosing is usually sitting somewhere at or below those opening steps, indefinitely.
Both molecules are GLP-1 receptor agonists: they mimic glucagon-like peptide-1, a hormone the gut releases after eating that slows gastric emptying and signals fullness to the brain. Tirzepatide additionally activates the GIP receptor, a second gut hormone pathway. In plain terms, these drugs borrow a signal your body already uses and amplify it. A smaller dose amplifies it less. Our guides to semaglutide vs tirzepatide and to Wegovy vs Zepbound cover the mechanism and the brands in more depth.
Does GLP-1 microdosing actually work?
This is where the public conversation splits unhelpfully in two. Academic medical centers, several of which have published on this in the last year, tend to answer โthere is no evidence for itโ. Clinics selling the service tend to answer โyes, with fewer side effectsโ. Both answers skip the data that exists.
The most relevant published evidence is OโNeil and colleagues in The Lancet in 2018: a randomized, double-blind, placebo and active controlled, dose-ranging phase 2 trial of semaglutide in 957 adults with obesity and without diabetes, across 71 sites in eight countries, with weight loss at 52 weeks as the primary endpoint. Crucially for this question, it tested doses far below anything later approved.
| Daily semaglutide dose | Weight loss at 52 weeks | What this tells you |
|---|---|---|
| Placebo | -2.3% | The baseline that any dose has to beat |
| 0.05ย mg | -6.0% | The lowest dose tested, and clearly better than placebo |
| 0.1ย mg | -8.6% | Still well below any approved dose |
| 0.2ย mg | -11.6% | Where the curve begins to flatten |
| 0.3ย mg | -11.2% | No gain over 0.2 mg in this trial |
| 0.4ย mg | -13.8% | The highest dose tested |
Read that honestly and it cuts both ways. Lower doses are not placebo: the smallest dose in the trial produced roughly two and a half times the placebo result. But the highest dose tested produced more than twice the weight loss of the lowest, so a person choosing to stay low is, on average, accepting a materially smaller result.
Two caveats matter and are usually dropped. First, this trial used daily injections, while the approved weight management products are weekly, so the milligram figures are not directly transferable to a weekly schedule. Second, it was a dose-finding study, not a test of microdosing as a long-term strategy, and it ran for 52 weeks rather than for years. It tells you the shape of the dose-response curve. It does not tell you that staying low indefinitely is safe, effective or sensible for you.
For comparison at the other end of the range, SURMOUNT-5 (Aronne and colleagues, New England Journal of Medicine, 2025) compared the two molecules at maximum tolerated doses over 72 weeks and found 20.2% weight loss with tirzepatide and 13.7% with semaglutide. Those are full-dose results, achieved by people who titrated all the way up and stayed there.
Why do people try it?
Three reasons come up repeatedly, and they are not equally well supported.
- Tolerability. This is the strongest argument, and it is a recognised clinical one. Gastrointestinal side effects cluster during dose escalation, and a patient who cannot get past a step is a patient who stops treatment altogether. A letter in Diabetes Care in 2025 by Komรฉ, Buse, Klein and colleagues described fractional dosing as an unconventional but tailored approach used to maximise therapeutic benefit, minimise adverse effects and manage supply constraints. Note the framing: a clinician adapting to a specific patient, not a protocol marketed to everyone.
- Cost. Usually assumed, often wrong. See the section below.
- Metabolic or longevity benefit at low dose. This is the claim with the least behind it, and it deserves its own section.
Want the dose decided by your labs, not by a chart?
Generational Health runs a physician-supervised medical weight loss program in Beverly Hills using compounded semaglutide and tirzepatide. We set and adjust your dose around your history, your tolerance and your bloodwork, and we will tell you plainly when a lower dose is reasonable and when it is simply under-treating you.
Three month program minimum. The initial consultation can be waived with the purchase of a package. The program is priced per month, not per milligram, so a lower dose does not reduce the program cost. GLP-1 medication is prescribed only by a licensed provider after a medical evaluation and is not right for everyone. Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA does not verify the safety or effectiveness of compounded drugs. Individual results vary.
The longevity claim, and what the evidence does not support
The version of microdosing that has travelled furthest on social media is not really about weight. It is the idea that a very small, continuous GLP-1 dose confers metabolic, anti-inflammatory or anti-aging benefit in people who are not trying to lose weight at all.
Stated plainly: there are no human trials testing a low-dose GLP-1 regimen for longevity, biological aging or general inflammation, and no regulator has approved any GLP-1 for those purposes. The interest is not baseless, because these drugs do have demonstrated effects beyond weight in approved populations. Semaglutide, under the Wegovy brand, carries FDA approval for reducing major adverse cardiovascular events in adults with established cardiovascular disease who also have obesity or overweight, and an accelerated approval for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. But every one of those approvals rests on trials in defined patient groups at full therapeutic doses. Extrapolating from โit reduces cardiovascular events in high-risk patients at 2.4 mgโ to โa microdose will slow my agingโ is not a small step. It is an unevidenced one.
If longevity and metabolic health are the actual goal, that is a broader conversation than one molecule. Our comparison of GLP-1 and NAD+ for metabolic health and longevity sets out where each one sits, and comprehensive blood testing is a more defensible starting point than a drug chosen in advance.
The cost assumption that often turns out wrong
Many people arrive at microdosing expecting it to cut the bill proportionally. It frequently does not, and it is worth understanding why before building a plan around it.
Compounded medication is typically supplied and priced by the vial, and physician-supervised programs are generally priced per month of care rather than per milligram of drug. That care, the evaluation, the monitoring, the follow-up and the clinical time, does not become cheaper because the dose is smaller. Our own program is an example: it is priced monthly, so a lower dose does not reduce what you pay. Several academic medical centers have made the same point publicly this year. If cost is the real constraint, say so directly at consultation, because there are more honest levers to pull than quietly under-dosing.
Risks, side effects and who should not do this
A lower dose reduces the likelihood and severity of the dose-related gastrointestinal effects, but it does not change the safety profile of the molecule or remove any contraindication. Everything below applies at any dose.
Both semaglutide and tirzepatide carry a boxed warning for thyroid C-cell tumors, based on rodent studies, and both are contraindicated in:
- A personal or family history of medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia syndrome type 2 (MEN 2).
- A prior serious hypersensitivity reaction to the medication or any of its components.
Beyond the formal contraindications, these medications need careful review in pregnancy or when pregnancy is planned, in a history of pancreatitis, in significant gastrointestinal disease such as gastroparesis, in active gallbladder disease, and in diabetic retinopathy. Common side effects remain nausea, constipation or diarrhea, abdominal discomfort and heartburn; our guide to GLP-1 side effects and how to manage them covers what helps.
Two risks are specific to the microdosing trend and rarely stated. The first is measurement error: drawing a fraction of a dose from a vial or dialling a partial dose on a pen introduces inaccuracy, and the smaller the intended dose, the larger a small error becomes in proportion. The second is self-directed dosing, often guided by a chart found online and a product bought from an unregulated source. That combination, an unverified product and a dose nobody clinically responsible has set, is where the genuine harm in this category tends to come from.
There is also an outcome worth naming that is not a side effect at all: under-treatment. Someone with obesity and a real medical indication who stays at a token dose for a year because a wellness trend framed it as the sophisticated choice has not avoided a risk. They have spent a year not being treated.
What a responsible low-dose conversation looks like
None of this makes a lower dose wrong. It makes it a clinical decision rather than a lifestyle choice. In practice a defensible version looks like this: a full evaluation and baseline labs first; a clear target that is not simply โthe smallest amount possibleโ; a dose set and adjusted by a prescriber who is monitoring you; attention to protein intake and resistance training, because a meaningful share of weight lost on any GLP-1 is lean mass; and a willingness to move the dose up if the result is not there, rather than treating the low dose as the point. If you are weighing medication against other routes, our overviews of GLP-1 for weight loss without diabetes and peptides studied for weight loss set out the landscape.
Medical Disclaimer
These statements have not been evaluated by the Food and Drug Administration. This article is for educational purposes only, is not medical advice, and is not intended to diagnose, treat, cure, or prevent any disease. No GLP-1 medication is FDA-approved for use at a microdose, and no GLP-1 medication is approved for longevity, anti-aging or general metabolic optimization; any such use is off-label. Dosing figures reported here come from published clinical trials and FDA labels and are cited for educational context only. They are not a protocol, not a recommendation, and must not be used to self-dose. Semaglutide and tirzepatide are prescription medications that must be prescribed and supervised by a licensed healthcare provider following an individual medical evaluation, and they are not appropriate for everyone, including people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Generational Health (formerly Robertson Wellness and Aesthetics), Beverly Hills, prescribes compounded semaglutide and tirzepatide, which are not FDA-approved; the FDA does not verify the safety or effectiveness of compounded drugs. Trial figures describe group averages under study conditions. Individual results vary and are not guaranteed. Always consult a qualified healthcare provider before beginning or changing any treatment.
Frequently asked questions
What is considered a microdose for GLP-1?
There is no official definition, and that is part of the problem with the term. It is generally used for any dose deliberately kept below the approved maintenance range, which for semaglutide means below 2.4 mg weekly and for tirzepatide below 5 mg weekly. In practice people usually mean sitting at or under the opening titration step indefinitely rather than escalating through it.
What is the best microdosing protocol?
There is not one, and any page presenting a definitive microdosing chart is presenting a convention rather than an approved or trial-validated schedule. No regulator has approved a microdose regimen and no randomized trial has tested microdosing as a long-term strategy. A dose that is appropriate for you is set by a prescriber using your history, your tolerance and your labs.
How much is a microdose of semaglutide?
The honest answer is that it depends who you ask, because the term is not standardised. For reference, the lowest dose ever tested in a randomized semaglutide weight trial was 0.05 mg daily, which produced 6.0% weight loss at 52 weeks against 2.3% for placebo. That was a daily regimen in a dose-finding study, not a weekly maintenance schedule, so it should not be read across to the weekly products as a milligram equivalent.
What are the risks of GLP-1 microdosing?
The contraindications and the boxed warning for thyroid C-cell tumors apply at every dose, so a smaller dose does not make an unsuitable patient suitable. Three risks are specific to the practice: dosing inaccuracy when drawing or dialling a fraction, product from unregulated sources when the regimen is self-directed, and under-treatment, where someone with a real medical indication stays at a token dose and loses a year of progress.
Does microdosing a GLP-1 save money?
Often less than people expect. Compounded medication is usually supplied by the vial and supervised programs are generally priced per month of care, so the clinical time and monitoring do not scale down with the dose. If cost is the constraint, it is better raised openly at consultation than managed by quietly taking less.
Can you microdose for longevity rather than weight loss?
People do, but there is no human trial supporting it. No GLP-1 is approved for longevity, biological aging or general inflammation, and the cardiovascular and liver approvals that exist were earned in defined patient populations at full therapeutic doses, not at microdoses in healthy people. Framing it accurately matters: this is an unevidenced off-label use, not an established longevity protocol.
Where to go from here
If the question underneath your search is whether a smaller dose could work for you, that is a reasonable question and it has a real answer, but it is a clinical one. Generational Health offers physician-supervised medical weight loss in Beverly Hills, minutes from Cedars-Sinai, with evaluation and bloodwork first and ongoing dose adjustment rather than a fixed chart. Our clinical team will also tell you when the honest answer is that a low dose is not going to get you where you want to go. Request a consultation to talk it through.
Written and medically reviewed by Biana Borchenko, FNP-BC, Family Nurse Practitioner, Board-Certified, with fellowship training through the American Academy of Anti-Aging Medicine (A4M), at Generational Health (formerly Robertson Wellness and Aesthetics), Beverly Hills. Biana leads the clinicโs medical weight management program, where every GLP-1 plan begins with a review of personal and family history, current medications and laboratory work, gradual dose escalation to limit gastrointestinal side effects, and attention to protein intake and resistance training to preserve muscle mass.
Sources cited in this article: OโNeil PM, Birkenfeld AL, McGowan B, et al. โEfficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.โ The Lancet, 2018;392(10148):637-649. Komรฉ AM, Chandran MM, Tungate Lopez SS, Buse JB, Klein KR. โOne Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens.โ Diabetes Care, 2025;48(3):e25-e27. Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. โTirzepatide as Compared with Semaglutide for the Treatment of Obesity.โ New England Journal of Medicine, 2025;393(1):26-36. US Food and Drug Administration, WEGOVY (semaglutide) prescribing information. US Food and Drug Administration, ZEPBOUND (tirzepatide) prescribing information.
